Physicians' Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians' Education Resource designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Rapid Reviews in Oncology: Emerging Options in the Treatment of Breast Cancer June 2008
Jun 25-Jul 2, 2008, Dallas, TX
1.5 AMA PRA Category 1 Credits™
Release Date: July 02, 2008
Expiration Date: July 02, 2009
The Web pages and Web-based applications require a minimum Web browser of Microsoft Internet Explorer 5.5 or higher, Mozilla Firefox 1.0 or higher, or another compatible Web browser.
If you are not sure of the version of your browser, select Help in the menu bar of your browser, then select About.
PC Users:
If you need to upgrade your Web browser, follow one of the links listed below:
Macintosh Users:
Compatible Web browsers include:
Complete the evaluation, pretest, and posttest by July 2, 2009 to receive your certificate of credit online.
Disclosure Policy
It is the policy of Physicians' Education Resource to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Physicians' Education Resource requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. Physicians' Education Resource has implemented a mechanism to identify and resolve all conflicts of interest prior to the activity.
This CME activity might include discussion of investigational and/or unlabeled uses of drugs. If the activity includes discussion of investigational and/or unlabeled uses of a drug, specific information is delineated by the faculty during the presentation. Please refer to the full prescribing information for each drug discussed in this activity for FDA-approved dosing, indications, and warnings.
This educational activity is supported by a grant from: Bristol-Myers Squibb and Genentech BioOncology .
Software RequirementsThe Web pages and Web-based applications require a minimum Web browser of Microsoft Internet Explorer 5.5 or higher, Mozilla Firefox 1.0 or higher, or another compatible Web browser.
If you are not sure of the version of your browser, select Help in the menu bar of your browser, then select About.
PC UsersMacintosh Users
Compatible Web browsers include
Physicians’ Education Resource (PER) makes reasonable efforts to ensure that privacy issues are handled responsibly. PER does not sell or share your information with other organizations that are not directly involved in this process. If you have further concerns, you may contact us at (888) 949-0045.
All rights reserved. No part of this activity may be translated, reproduced, stored, or transmitted by any means or in any type of media form including electronic, mechanical photocopying, recording, broadcasting, or otherwise without prior permission from the publisher.
©Copyright 2008 by Physicians’ Education Resource. No material may be reproduced in whole or in part, in any form, without written permission from the publisher.
All correspondence should be directed to:
Editor, Rapid Reviews in Oncology: Emerging Options in the Treatment of Breast Cancer
Physicians' Education Resource
3500 Maple Ave.
Suite 700
Dallas, TX 75219
Phone: (214) 367-3456
Fax: (214) 367-3304
E-mail: editor@pergrouplp.com
An educational grant for this activity was provided by: